- Leverage & Inverse ETPs
- Instruments
- Why Us
Your capital is at risk if you invest. You could lose all your investment. Please see the full risk warning here.
On the 1st of October 2025, Eli Lilly and Company made headlines after its stock surged by 8.75% in a single trading session. The move was driven by a combination of regulatory approvals, billion-dollar government contracts, and favourable policy developments in the United States. For Wall Street, the rally was more than a short-term technical move; it underscored the company’s strengthened position in an increasingly competitive and politically sensitive pharmaceutical environment.
The Indianapolis-based drugmaker, already one of the most valuable pharmaceutical companies globally with a market capitalization of $781 billion, has demonstrated that its growth strategy is paying off. From oncology breakthroughs to diabetes and weight-loss therapies, Eli Lilly has built a multi-pronged growth story that resonates with both institutional investors and retail traders.
At the centre of Eli Lilly’s rally was a series of Food and Drug Administration approvals, most notably the authorization of Inluriyo, a treatment for advanced breast cancer. 1 The approval is not only a significant milestone for patients but also a commercial catalyst for the company, with likely strong demand in both the U.S. and European markets. Inluriyo expands Eli Lilly’s presence in oncology, a therapeutic area where innovation translates directly into market share and premium pricing.
Beyond oncology, the company is also making strides in diabetes treatments, an area of tremendous global demand. Orforglipron, Lilly’s oral GLP-1 therapy, outperformed for 52 weeks Novo Nordisk’s oral semaglutide in Phase 3 clinical trials for type 2 diabetes. This result positions Eli Lilly as a direct competitor to Novo Nordisk in one of the rapidly-growing segments of the pharmaceutical industry. Given the rising prevalence of obesity and type 2 diabetes worldwide, Eli Lilly’s expanding portfolio will likely capture substantial market share and provide long-term growth momentum.
Eli Lilly’s rally was also supported by an $8 billion contract with the U.S. Department of Veterans Affairs. This multi-year agreement not only provides a predictable revenue stream but also signals trust in Lilly’s ability to deliver reliable and effective treatments at scale. In the current political environment, where pharmaceutical pricing remains under scrutiny, securing government contracts of this magnitude represents both financial stability and reputational strength.
In addition to securing major contracts, on the 23rd of September Eli Lilly has announced a $6.5 billion investment in a new manufacturing facility in Houston, Texas. 2 The site will focus on the production of small-molecule medicines, including Orforglipron, thereby strengthening domestic supply chains. Earlier in the month Lilly announced that it plans to build a $5 billion manufacturing facility in Virginia. 3 These investments are particularly strategic given the United States’ growing focus on reducing reliance on overseas pharmaceutical manufacturing. By expanding within the U.S., Eli Lilly has also secured an exemption from the recently imposed 100% tariffs on branded pharmaceuticals. Competitors that depend on imported production face significant cost headwinds, while Lilly’s U.S.-based expansion offers both regulatory protection and operational efficiency.
While headlines have focused on regulatory wins and strategic contracts, Eli Lilly’s financial performance offers further justification for investor enthusiasm. The company reported second-quarter revenue of $15.55 billion, supported by a gross margin of 84.3% and net income of $5.66 billion. 4
Return on equity stands at an impressive 87.91%, highlighting management’s ability to generate strong returns on capital deployed. However, investors are also keeping a close eye on Lilly’s balance sheet, where a debt-to-equity ratio of 1.86 suggests that the company has relied heavily on leverage to finance expansion. While debt has fuelled growth and capacity-building, it also introduces risks should market conditions tighten or regulatory changes undermine profitability.
The Trump administration has prioritized direct-to-consumer drug pricing reforms, culminating in the announcement of TrumpRx.gov, a government-run website expected to launch in early 2026. The site will enable U.S. patients to purchase prescription drugs directly from manufacturers at discounted prices, cutting out intermediaries such as insurers and pharmacy benefit managers. 5
Pfizer was the first major pharmaceutical company to sign an agreement under the new framework, agreeing to reduce prices on select medications by up to 85% in exchange for a three-year exemption from pharmaceutical tariffs. Eli Lilly has confirmed that it is in active discussions with the administration to expand patient access through similar agreements. While the political rhetoric around drug pricing remains intense, we view the voluntary cooperation model as an opportunity rather than a threat. By embracing negotiated pricing, companies like Eli Lilly may avoid harsher regulatory interventions while simultaneously broadening patient access.
The announcement of the TrumpRx initiative lifted the S&P 500 Pharmaceuticals Index, with Eli Lilly emerging as a significant gainer. The positive sector reaction reflects investor relief that pricing reforms may prove more symbolic than disruptive to pharmaceutical earnings.
Eli Lilly’s ascent comes at a time of intense competition in the pharmaceutical sector. The diabetes and obesity markets, led by GLP-1 therapies, have become battlegrounds for major drugmakers such as Novo Nordisk, Pfizer, and Amgen. Lilly’s success with Mounjaro and Zepbound has already established the company as aleading company in the market, but ongoing innovation will be critical to maintaining its advantage.
What differentiates Lilly is its ability to leverage existing therapies into new areas of research, such as the potential crossover between weight-loss drugs and Alzheimer’s treatment. Growing evidence linking metabolic health to cognitive decline has created speculation that Lilly’s existing portfolio could eventually expand into the neurodegenerative disease market, representing a multi-billion-dollar opportunity. Should these avenues prove viable, Lilly would strengthen its position as a diversified pharmaceutical powerhouse with exposure across multiple high-growth therapeutic areas.
Eli Lilly’s rally was amplified by a surge in bullish options activity that created a self-reinforcing tailwind for the stock. Call option volumes spiked to nearly four times their daily average, as traders positioned aggressively for further upside in Eli Lilly shares. This wave of options buying added momentum to the stock price, generating a technical feedback loop that sustained the day’s advance.
The heightened activity pushed implied volatility higher, a signal that investors expect significant price movement in the near term. This also suggests that market participants view Eli Lilly’s current prices and growth trajectory as attractive. The options market is sending a clear message: momentum is building, and confidence in Eli Lilly’s future remains high.
Source: TradingView
After peaking at a record high of $972.53 in August 2024, Eli Lilly’s stock reversed course, entering a bear market phase that lasted roughly a year. During this period, the share price gradually declined, hitting a low of $623.78 in August 2025, which appears to mark the bottom of the downtrend.
Since the August low, the stock has staged a strong recovery, with recent price action breaking above its long-term downward trend line. This breakout signals the down trend is likely to be over and suggests that higher price levels are likely to unfold over the medium to long term. The current rally has also retraced to the 61.8% Fibonacci level calculated from the August 2024 high to the August 2025 low, reinforcing the view that the previous downtrend may be over.
While a short-term pullback could occur as the stock is in overbought territory, a re-test of the previous all-time high of $972.53 appears increasingly probable in the coming months. Looking further ahead, the potential for the stock to exceed its prior record and set new highs is gaining credibility, supported by both technical signals and the company’s strong fundamental outlook.
Despite the optimism surrounding Eli Lilly, the company faces a number of challenges. High leverage requires careful financial management, particularly if macroeconomic conditions tighten or interest rates rise. Research and development expenses continue to grow, with pharmaceutical innovation requiring both time and capital. Clinical trials remain inherently risky, and any significant setback could dampen investor enthusiasm.
On the policy side, while the Trump administration’s current direction has eased investor concerns, drug pricing will remain a contentious political issue. Any future legislative changes could revive calls for stricter controls, creating long-term uncertainty. Additionally, market volatility and investor sentiment can change quickly in a sector where news of trial results, regulatory reviews, or competitor breakthroughs can drive large price swings.
Eli Lilly’s leadership in oncology, diabetes, and weight-loss treatments, coupled with its willingness to engage constructively with U.S. policymakers, has positioned it as a clear winner in the current pharmaceutical environment.
However, investors must balance enthusiasm with caution. Elevated debt levels, rising R&D costs, and ongoing regulatory uncertainties remain important factors to monitor. For long-term investors, Lilly’s diversified portfolio, robust pipeline, and strategic expansion into U.S. manufacturing suggest that the company has the resilience to go through challenges and continue driving shareholder value.
For now, the message from Wall Street is clear: Eli Lilly is not merely riding the wave of a sector rally. It is actively shaping the future of the pharmaceutical industry, and investors are betting that after a year on the sidelines, its bullish momentum is only just beginning.
Professional investors looking for magnified exposure to Eli Lilly may consider Leverage Shares +3x Long Eli Lilly or -3x Short Eli Lilly ETPs.
Footnotes:
Websim is the retail division of Intermonte, the primary intermediary of the Italian stock exchange for institutional investors. Leverage Shares often features in its speculative analysis based on macros/fundamentals. However, the information is published in Italian. To provide better information for our non-Italian investors, we bring to you a quick translation of the analysis they present to Italian retail investors. To ensure rapid delivery, text in the charts will not be translated. The views expressed here are of Websim. Leverage Shares in no way endorses these views. If you are unsure about the suitability of an investment, please seek financial advice. View the original at
Your capital is at risk if you invest. You could lose all your investment. Please see the full risk warning here.
Share this:
INVESTOR TYPE:
LOCATION:
Never miss out on important announcements. Get premium content ahead of the crowd. Enjoy exclusive insights via the newsletter only.
